Sector: HealthcareIndustry: Drug Manufacturers - GeneralCIK: 0000318154
Market Cap187.85 Bn
P/E24.37
P/S5.11
Div. Yield0.03
ROIC (Qtr)0.12
Total Debt (Qtr)54.60 Bn
Revenue Growth (1y) (Qtr)8.58
Add ratio to table...
About
Amgen Inc., commonly known as AMGN, is a prominent player in the biotechnology industry. The company is dedicated to discovering, developing, manufacturing, and delivering innovative medicines to address some of the world's most challenging diseases. Amgen's operations are focused on the human therapeutics segment, which involves the development, manufacturing, and marketing of biotechnology-derived products such as therapeutic proteins, vaccines, and monoclonal antibodies.
In its day-to-day activities, Amgen is engaged in the creation of biotechnology-derived...
Amgen Inc., commonly known as AMGN, is a prominent player in the biotechnology industry. The company is dedicated to discovering, developing, manufacturing, and delivering innovative medicines to address some of the world's most challenging diseases. Amgen's operations are focused on the human therapeutics segment, which involves the development, manufacturing, and marketing of biotechnology-derived products such as therapeutic proteins, vaccines, and monoclonal antibodies.
In its day-to-day activities, Amgen is engaged in the creation of biotechnology-derived products, which are then marketed globally. The United States serves as the company's largest market, but Amgen has a significant presence in Europe, Asia Pacific, and Japan as well. The company's product portfolio includes Prolia, ENBREL, Otezla, XGEVA, Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO, TEPEZZA, and KRYSTEXXA, among others. These products are used to treat a variety of diseases, including cancer, inflammation, and bone disorders.
Amgen's position within the biotechnology industry is a strong one, but it is not without competition. The company faces significant competition from other biotechnology companies, such as Pfizer, Johnson & Johnson, and Novartis. However, Amgen has established a competitive advantage through its manufacturing capabilities. The company believes it is a leader in the manufacture of biologics and operates a global manufacturing network with facilities in the United States, Europe, and Asia. These facilities are designed to produce high-quality products and incorporate various quality control measures to ensure the integrity of Amgen's products.
Amgen's products are marketed to healthcare providers, private payers, government payers, and pharmacy benefit managers (PBMs). Reimbursement is a critical factor in the sales of Amgen's products, and the company provides negotiated rebates to healthcare providers, private payers, government payers, and PBMs. The company is also required to provide rebates or discounts on its products that are reimbursed through certain government programs, including Medicare and Medicaid. Payers continue to institute cost reduction and containment measures, such as formulary exclusions, higher patient co-pays or coinsurance obligations, and stricter utilization management criteria, which can limit patient access to Amgen's products.
In addition to its current product portfolio, Amgen has a robust pipeline of product candidates in various stages of development. These include tarlatamab, LUMAKRAS/LUMYKRAS, and EVENITY. The company has also expanded its portfolio through acquisitions, such as Horizon Therapeutics, which has added to Amgen's rare disease treatment offerings.
Amgen's products are distributed through its own sales force and third-party distributors in various territories, including the United States, Europe, Asia Pacific, and Japan. The company operates distribution centers in Puerto Rico, Kentucky, California, and the Netherlands for worldwide distribution of its commercial and clinical products.
Amgen’s 2025 results demonstrate that the company’s diversified portfolio is delivering double‑digit revenue and EPS growth, a performance that underlines the firm’s ability to sustain momentum across multiple therapeutic areas. The firm’s 14 products surpassing the $1 billion sales threshold, coupled with a 13‑product double‑digit sales growth cohort, signal a broad base of high‑margin revenue generators that can absorb headwinds in any single segment. Moreover, the company’s strategic focus on early‑stage life‑cycle products such as Repatha, Evenity, and Testspire—each having achieved 30 %+ growth in 2025—provides a proven model for rapid scaling and margin expansion that can be replicated across its pipeline. This combination of high‑growth brands and a disciplined pipeline build is a key catalyst for sustained valuation upside.
{bullet} Repatha remains the only PCSK9 inhibitor backed by robust outcome data from the Vesalius trial, which established a 25 % relative risk reduction in first major cardiovascular events. The FDA’s endorsement of the drug for both primary and secondary prevention expands its addressable market from the approximately 100 million LDL‑cholesterol patients worldwide to the entire high‑risk cohort, including those who have not experienced a prior event. Coupled with the company’s direct‑to‑patient program, Amgen has the distribution leverage to capture the growing trend toward proactive, evidence‑based LDL management, positioning the drug as a key revenue driver well into the next decade.
{bullet} In the obesity space, the introduction of the once‑monthly or even quarterly dosing of MariTide (Meritide) provides a paradigm shift that could capture patients disenchanted with weekly GLP‑1 therapies. The company’s commitment to six Phase‑III studies—spanning obesity, diabetes, heart failure, and sleep apnea—creates a diversified clinical evidence base that can support multiple indications and dosing regimens. If the data confirm the hypothesized efficacy–tolerability trade‑off, MariTide could secure a strong foothold in a market that is currently fragmented and price‑sensitive, while also mitigating the cannibalization risk posed by newer oral or short‑acting competitors.
{bullet} Opaziran, a small‑interfering RNA targeting Lp(a), targets an under‑treated cardiovascular risk factor that carries a high residual risk burden. The drug’s mechanism offers a unique value proposition that differentiates it from existing lipid‑lowering agents, potentially capturing a niche segment of patients with high Lp(a) and a strong unmet need for risk reduction. Positive outcomes in the OCEAN‑A study could unlock a high‑margin product that is highly valuable for both specialty pharmacy and direct‑to‑patient channels, further diversifying Amgen’s revenue streams.
{bullet} The rare‑disease portfolio, anchored by the newly approved Aplisna (IgG4‑related disease) and Eplizna (generalized myasthenia gravis), has shown a 73 % sales increase for Aplisna in 2025, driven by rapid uptake across rheumatology, gastroenterology, and neurology. These drugs are delivered via a 6‑month dosing schedule, delivering high adherence and a favorable cost‑effectiveness profile that can appeal to payers looking to reduce reliance on steroids. The pipeline also contains promising programs in autoimmune hepatitis and CIDP, with a strong rationale for B‑cell depletion that could address sizable patient cohorts and translate into incremental sales growth.
{bullet} Amgen’s biosimilar strategy has delivered a $13 billion cumulative sales lift since 2018, and the current wave of biosimilar launches—ABP‑206 and ABP‑234 to Opdivo and Keytruda respectively—will add further revenue and provide a buffer against blockbuster patent cliffs. Biosimilar margins, while lower than originators, remain high due to the company’s manufacturing efficiency and strong relationships with specialty pharmacies. This diversified revenue mix protects Amgen from the cyclical risk associated with patent expirations in other segments.
{bullet} The company’s investment in AI across the drug development pipeline, from discovery to manufacturing, offers a hidden catalyst that can accelerate time‑to‑market and reduce R&D cost per drug. The reported $7.2 billion of R&D spend in 2025, a 22 % increase year‑over‑year, demonstrates Amgen’s commitment to pipeline depth and its willingness to fund early‑stage science that could yield high‑barrier products. Even if individual assets fail, the cumulative probability of generating at least one blockbuster over the next decade is materially higher than industry peers that allocate fewer resources to R&D.
{bullet} Amgen’s free cash flow of $8.1 billion in 2025, combined with a disciplined capital allocation strategy that includes a $2.6 billion capex plan for 2026, underscores the firm’s financial resilience. The company is positioned to reinvest in late‑stage clinical development, expand manufacturing capacity for high‑volume products like Repatha, and fund potential acquisitions that could accelerate the addition of complementary technologies. These cash flows also support a robust dividend and share‑repurchase program, providing additional upside to shareholders.
{bullet} The company’s strategic partnership framework—highlighted by its continued collaboration with Kewa Kirin on rocotinlimab and the potential for bolt‑on deals—offers a pathway to expand the product portfolio beyond its internal pipeline. The ability to secure late‑stage assets that fit Amgen’s therapeutic focus allows the firm to mitigate internal development risk while capturing incremental revenue. The synergy between Amgen’s commercialization expertise and partner technologies enhances the likelihood of successful market entry.
{bullet} Finally, the overall market sentiment toward Amgen has been positive, with analysts projecting a 2026 revenue range of $37 billion to $38.4 billion and an EPS range that exceeds consensus estimates. This optimism is anchored in the company’s proven commercial track record and its pipeline depth, which collectively create a durable growth engine that investors are likely to undervalue.
Amgen’s 2025 results demonstrate that the company’s diversified portfolio is delivering double‑digit revenue and EPS growth, a performance that underlines the firm’s ability to sustain momentum across multiple therapeutic areas. The firm’s 14 products surpassing the $1 billion sales threshold, coupled with a 13‑product double‑digit sales growth cohort, signal a broad base of high‑margin revenue generators that can absorb headwinds in any single segment. Moreover, the company’s strategic focus on early‑stage life‑cycle products such as Repatha, Evenity, and Testspire—each having achieved 30 %+ growth in 2025—provides a proven model for rapid scaling and margin expansion that can be replicated across its pipeline. This combination of high‑growth brands and a disciplined pipeline build is a key catalyst for sustained valuation upside.
{bullet} Repatha remains the only PCSK9 inhibitor backed by robust outcome data from the Vesalius trial, which established a 25 % relative risk reduction in first major cardiovascular events. The FDA’s endorsement of the drug for both primary and secondary prevention expands its addressable market from the approximately 100 million LDL‑cholesterol patients worldwide to the entire high‑risk cohort, including those who have not experienced a prior event. Coupled with the company’s direct‑to‑patient program, Amgen has the distribution leverage to capture the growing trend toward proactive, evidence‑based LDL management, positioning the drug as a key revenue driver well into the next decade.
{bullet} In the obesity space, the introduction of the once‑monthly or even quarterly dosing of MariTide (Meritide) provides a paradigm shift that could capture patients disenchanted with weekly GLP‑1 therapies. The company’s commitment to six Phase‑III studies—spanning obesity, diabetes, heart failure, and sleep apnea—creates a diversified clinical evidence base that can support multiple indications and dosing regimens. If the data confirm the hypothesized efficacy–tolerability trade‑off, MariTide could secure a strong foothold in a market that is currently fragmented and price‑sensitive, while also mitigating the cannibalization risk posed by newer oral or short‑acting competitors.
{bullet} Opaziran, a small‑interfering RNA targeting Lp(a), targets an under‑treated cardiovascular risk factor that carries a high residual risk burden. The drug’s mechanism offers a unique value proposition that differentiates it from existing lipid‑lowering agents, potentially capturing a niche segment of patients with high Lp(a) and a strong unmet need for risk reduction. Positive outcomes in the OCEAN‑A study could unlock a high‑margin product that is highly valuable for both specialty pharmacy and direct‑to‑patient channels, further diversifying Amgen’s revenue streams.
{bullet} The rare‑disease portfolio, anchored by the newly approved Aplisna (IgG4‑related disease) and Eplizna (generalized myasthenia gravis), has shown a 73 % sales increase for Aplisna in 2025, driven by rapid uptake across rheumatology, gastroenterology, and neurology. These drugs are delivered via a 6‑month dosing schedule, delivering high adherence and a favorable cost‑effectiveness profile that can appeal to payers looking to reduce reliance on steroids. The pipeline also contains promising programs in autoimmune hepatitis and CIDP, with a strong rationale for B‑cell depletion that could address sizable patient cohorts and translate into incremental sales growth.
{bullet} Amgen’s biosimilar strategy has delivered a $13 billion cumulative sales lift since 2018, and the current wave of biosimilar launches—ABP‑206 and ABP‑234 to Opdivo and Keytruda respectively—will add further revenue and provide a buffer against blockbuster patent cliffs. Biosimilar margins, while lower than originators, remain high due to the company’s manufacturing efficiency and strong relationships with specialty pharmacies. This diversified revenue mix protects Amgen from the cyclical risk associated with patent expirations in other segments.
{bullet} The company’s investment in AI across the drug development pipeline, from discovery to manufacturing, offers a hidden catalyst that can accelerate time‑to‑market and reduce R&D cost per drug. The reported $7.2 billion of R&D spend in 2025, a 22 % increase year‑over‑year, demonstrates Amgen’s commitment to pipeline depth and its willingness to fund early‑stage science that could yield high‑barrier products. Even if individual assets fail, the cumulative probability of generating at least one blockbuster over the next decade is materially higher than industry peers that allocate fewer resources to R&D.
{bullet} Amgen’s free cash flow of $8.1 billion in 2025, combined with a disciplined capital allocation strategy that includes a $2.6 billion capex plan for 2026, underscores the firm’s financial resilience. The company is positioned to reinvest in late‑stage clinical development, expand manufacturing capacity for high‑volume products like Repatha, and fund potential acquisitions that could accelerate the addition of complementary technologies. These cash flows also support a robust dividend and share‑repurchase program, providing additional upside to shareholders.
{bullet} The company’s strategic partnership framework—highlighted by its continued collaboration with Kewa Kirin on rocotinlimab and the potential for bolt‑on deals—offers a pathway to expand the product portfolio beyond its internal pipeline. The ability to secure late‑stage assets that fit Amgen’s therapeutic focus allows the firm to mitigate internal development risk while capturing incremental revenue. The synergy between Amgen’s commercialization expertise and partner technologies enhances the likelihood of successful market entry.
{bullet} Finally, the overall market sentiment toward Amgen has been positive, with analysts projecting a 2026 revenue range of $37 billion to $38.4 billion and an EPS range that exceeds consensus estimates. This optimism is anchored in the company’s proven commercial track record and its pipeline depth, which collectively create a durable growth engine that investors are likely to undervalue.
Despite the company’s optimistic outlook, Amgen faces a significant patent cliff that threatens to erode its high‑margin blockbuster revenue streams. The expiration of key patents, notably for the bone‑builder Evenity and the PCSK9 inhibitor Repatha, could open the door to cheaper biosimilar or generic challengers that may undercut prices and reduce market share. While the company forecasts modest net price declines for Repatha in 2026, the mid‑single‑digit reductions could still erode margins, especially if payers accelerate price compression across the cardiometabolic portfolio.
{bullet} The growing influence of pharmacy benefit managers (PBMs) poses a persistent risk to Amgen’s pricing strategy. The recent shift by CVS Caremark to exclude Amgen’s Prolia and switch to lower‑cost biosimilars, driven by a desire to reduce drug spend, exemplifies the pressure PBMs exert on reimbursement tiers. Similar moves targeting other high‑cost specialty drugs could erode the company’s pricing power, particularly if payers demand greater discounts or risk‑based contracts that dilute profit margins.
{bullet} The obesity drug market is becoming increasingly saturated, with multiple competitors such as Novo Nordisk, Eli Lilly, and Pfizer launching oral or short‑acting alternatives. The direct‑to‑consumer pricing model, which Amgen has employed for Repatha, may be unsustainable if patients compare the relatively high cost of monthly or quarterly injections against cheaper weekly GLP‑1 injections or oral options. If reimbursement structures favor lower‑cost alternatives, Amgen could lose market share in a segment where patient adherence is already fragile.
{bullet} The company’s aggressive R&D spend, while creating pipeline depth, also increases financial risk. A 22 % increase in R&D expenditure to $7.2 billion in 2025, coupled with the addition of $300 million in business development, places pressure on operating margins. Should key late‑stage assets—Meritide, Opaziran, or Aplisna—fail to secure regulatory approval or commercial traction, the company may face significant write‑downs that would compress earnings and undermine investor confidence.
{bullet} Regulatory uncertainty remains a notable risk factor. The FDA’s request to withdraw Tavneos from the U.S. market, citing concerns about trial data, highlights the vulnerability of Amgen’s rare‑disease portfolio to regulatory scrutiny. Even if the company believes it can resolve the issue, the potential for adverse regulatory action could damage the company’s reputation and result in lost revenue streams. Additionally, the company’s Q&A session revealed evasive answers regarding reimbursement for Repatha, suggesting that payers may challenge the drug’s value proposition or question its pricing strategy.
{bullet} The company’s reliance on a few high‑profile drugs for a large portion of revenue makes it vulnerable to market concentration risk. Repatha, Evenity, and Testspire together account for a significant share of Amgen’s total sales, and any decline in utilization of these products—whether due to competition, pricing pressure, or changes in clinical guidelines—could disproportionately impact the company’s topline. The heavy dependence on these products also limits the company’s ability to pivot quickly in response to industry shifts.
{bullet} Amgen’s pipeline includes several high‑risk assets in relatively narrow therapeutic areas, such as the bispecific T‑cell engager Zalaritamab for prostate cancer and the CD40 ligand‑targeted therapy Desodoliveb for Sjogren’s disease. The clinical and commercial uncertainty surrounding these programs, combined with the high cost of late‑stage development, raises the probability that they may fail to reach market approval or achieve meaningful sales. Failure of these assets would reduce the company’s future revenue growth prospects and could negatively affect its valuation.
{bullet} The company’s strategy to expand into emerging markets, particularly China, may not deliver the expected growth if it encounters regulatory or distribution hurdles. While China has become a source of innovation, the company still faces the challenge of navigating differing regulatory pathways, patent enforcement issues, and local competition. Failure to successfully commercialize products in these markets could limit Amgen’s global growth potential.
{bullet} The broader macroeconomic environment—characterized by elevated inflation, rising interest rates, and potential tightening of credit—could dampen the company’s ability to raise capital and increase the cost of servicing existing debt. Amgen’s 2025 debt repayment of $6 billion, coupled with future capital expenditures, could constrain liquidity if market conditions deteriorate, potentially impacting its ability to fund R&D or pursue strategic acquisitions.
{bullet} Finally, the company’s 2026 revenue guidance, while optimistic, may not adequately account for the cumulative impact of 340B program utilization, PBM rebates, and price erosion. If the projected net price decline for Repatha accelerates, and if payers push for deeper discounts across other high‑margin products, the company’s actual revenue growth could fall short of expectations, triggering a valuation correction.
Despite the company’s optimistic outlook, Amgen faces a significant patent cliff that threatens to erode its high‑margin blockbuster revenue streams. The expiration of key patents, notably for the bone‑builder Evenity and the PCSK9 inhibitor Repatha, could open the door to cheaper biosimilar or generic challengers that may undercut prices and reduce market share. While the company forecasts modest net price declines for Repatha in 2026, the mid‑single‑digit reductions could still erode margins, especially if payers accelerate price compression across the cardiometabolic portfolio.
{bullet} The growing influence of pharmacy benefit managers (PBMs) poses a persistent risk to Amgen’s pricing strategy. The recent shift by CVS Caremark to exclude Amgen’s Prolia and switch to lower‑cost biosimilars, driven by a desire to reduce drug spend, exemplifies the pressure PBMs exert on reimbursement tiers. Similar moves targeting other high‑cost specialty drugs could erode the company’s pricing power, particularly if payers demand greater discounts or risk‑based contracts that dilute profit margins.
{bullet} The obesity drug market is becoming increasingly saturated, with multiple competitors such as Novo Nordisk, Eli Lilly, and Pfizer launching oral or short‑acting alternatives. The direct‑to‑consumer pricing model, which Amgen has employed for Repatha, may be unsustainable if patients compare the relatively high cost of monthly or quarterly injections against cheaper weekly GLP‑1 injections or oral options. If reimbursement structures favor lower‑cost alternatives, Amgen could lose market share in a segment where patient adherence is already fragile.
{bullet} The company’s aggressive R&D spend, while creating pipeline depth, also increases financial risk. A 22 % increase in R&D expenditure to $7.2 billion in 2025, coupled with the addition of $300 million in business development, places pressure on operating margins. Should key late‑stage assets—Meritide, Opaziran, or Aplisna—fail to secure regulatory approval or commercial traction, the company may face significant write‑downs that would compress earnings and undermine investor confidence.
{bullet} Regulatory uncertainty remains a notable risk factor. The FDA’s request to withdraw Tavneos from the U.S. market, citing concerns about trial data, highlights the vulnerability of Amgen’s rare‑disease portfolio to regulatory scrutiny. Even if the company believes it can resolve the issue, the potential for adverse regulatory action could damage the company’s reputation and result in lost revenue streams. Additionally, the company’s Q&A session revealed evasive answers regarding reimbursement for Repatha, suggesting that payers may challenge the drug’s value proposition or question its pricing strategy.
{bullet} The company’s reliance on a few high‑profile drugs for a large portion of revenue makes it vulnerable to market concentration risk. Repatha, Evenity, and Testspire together account for a significant share of Amgen’s total sales, and any decline in utilization of these products—whether due to competition, pricing pressure, or changes in clinical guidelines—could disproportionately impact the company’s topline. The heavy dependence on these products also limits the company’s ability to pivot quickly in response to industry shifts.
{bullet} Amgen’s pipeline includes several high‑risk assets in relatively narrow therapeutic areas, such as the bispecific T‑cell engager Zalaritamab for prostate cancer and the CD40 ligand‑targeted therapy Desodoliveb for Sjogren’s disease. The clinical and commercial uncertainty surrounding these programs, combined with the high cost of late‑stage development, raises the probability that they may fail to reach market approval or achieve meaningful sales. Failure of these assets would reduce the company’s future revenue growth prospects and could negatively affect its valuation.
{bullet} The company’s strategy to expand into emerging markets, particularly China, may not deliver the expected growth if it encounters regulatory or distribution hurdles. While China has become a source of innovation, the company still faces the challenge of navigating differing regulatory pathways, patent enforcement issues, and local competition. Failure to successfully commercialize products in these markets could limit Amgen’s global growth potential.
{bullet} The broader macroeconomic environment—characterized by elevated inflation, rising interest rates, and potential tightening of credit—could dampen the company’s ability to raise capital and increase the cost of servicing existing debt. Amgen’s 2025 debt repayment of $6 billion, coupled with future capital expenditures, could constrain liquidity if market conditions deteriorate, potentially impacting its ability to fund R&D or pursue strategic acquisitions.
{bullet} Finally, the company’s 2026 revenue guidance, while optimistic, may not adequately account for the cumulative impact of 340B program utilization, PBM rebates, and price erosion. If the projected net price decline for Repatha accelerates, and if payers push for deeper discounts across other high‑margin products, the company’s actual revenue growth could fall short of expectations, triggering a valuation correction.